Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

Homecas247062-33-5

247062-33-5

247062-33-5 structural image
Product Name: Abaloparatide
Formula: C174H300N56O49
Inquiry

CHEMICAL AND PHYSICAL PROPERTIES

Solubility Soluble

COMPUTED DESCRIPTORS

Molecular Weight 3961 g/mol
XLogP3 -20.9
Hydrogen Bond Donor Count 61
Hydrogen Bond Acceptor Count 60
Rotatable Bond Count 145
Exact Mass 3959.2738250 g/mol
Monoisotopic Mass 3958.2704702 g/mol
Topological Polar Surface Area 1740 Ų
Heavy Atom Count 279
Formal Charge 0
Complexity 9310
Isotope Atom Count 0
Defined Atom Stereocenter Count 0
Undefined Atom Stereocenter Count 34
Defined Bond Stereocenter Count 0
Undefined Bond Stereocenter Count 0
Covalently-Bonded Unit Count 1
Compound Is Canonicalized Yes

PRODUCT INTRODUCTION

description

Abaloparatide is an analog of PTHrP (parathyroid hormone-related protein). It was approved in April 28, 2017 by the FDA (as Tymlos) for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Abaloparatide is a synthetic peptide that is related to hPTHrP and has demonstrated in preclinical testing the potential to widen the anabolic window for bone therapeutics, stimulating bone formation with a limited effect on bone resorption and mineral mobilization. This could enable improved convenience over currently available anabolic therapies, resulting in greater compliance and, ultimately, greater benefit to patients. In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended abaloparatide be granted marketing authorization in Europe for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. In December 2022, the FDA indication for abaloparatide was expanded to include male patients in addition to postmenopausal women.

RELATED SUPPLIERS

Apicore Pharmaceuticals Pvt Ltd

1Y
product:247062-33-5 Abaloparatide 98%
All suppliers(1)